Tivenix
Tivenix offers a proprietary software diagnostic that uses machine learning to decode epigenetic signatures of Alzheimer’s disease from a simple blood plasma sample. The platform detects and characterizes neuronal loss with accuracy matching current clinical practice, and is engineered to integrate with other biomarker data for multi-modal assessment. It supports both initial diagnosis and ongoing monitoring of disease progression and treatment response.
- Healthcare Technology
- Digital Health
- Artificial Intelligence
- Biotechnology
- Software Only
- Data & Analytics
Funding
Founders
Founder details are not available yet.
Product
Problem
Alzheimer’s disease and other neurodegenerative conditions are typically diagnosed through invasive procedures like lumbar punctures or costly, often inaccessible brain imaging, which delays early detection and hampers monitoring of disease progression and treatment response. This limits timely intervention and burdens healthcare systems with late-stage care.
Solution
Tivenix provides a proprietary software diagnostic that uses machine learning to decode epigenetic signatures of Alzheimer’s disease directly from a simple blood plasma sample. The platform analyzes complex DNA methylation patterns to detect and characterize neuronal loss, achieving accuracy that matches current best clinical practice for Alzheimer’s diagnostics. It is engineered to integrate seamlessly with data from other biomarkers, enabling a multi-modal approach to neurodegenerative disease assessment. The technology supports both initial diagnosis and ongoing monitoring of disease progression and therapeutic efficacy, offering a non-invasive alternative to traditional methods.
Target Audience
Primary customers are clinical diagnostic laboratories, neurologists, and research institutions focused on Alzheimer’s disease and other neurodegenerative disorders, as well as pharmaceutical companies conducting clinical trials that require biomarker-based patient monitoring.
Features
- Machine-learning algorithms that interpret complex epigenetic patterns in plasma to identify Alzheimer’s-specific signatures
- Non-invasive detection of neuronal loss from blood samples, validated in a proof-of-concept study
- Platform architecture designed for easy integration with other biomarker data sources
- Capability to monitor disease progression and response to treatment over time
- Expansion roadmap to cover additional neurodegenerative diseases beyond Alzheimer’s